Your browser doesn't support javascript.
loading
Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients ≥65 years old.
Eraj, Salman A; Jomaa, Mona K; Rock, Crosby D; Mohamed, Abdallah S R; Smith, Blaine D; Smith, Joshua B; Browne, Theodora; Cooksey, Luke C; Williams, Bowman; Temple, Brandi; Preston, Kathryn E; Aymard, Jeremy M; Gross, Neil D; Weber, Randal S; Hessel, Amy C; Ferrarotto, Renata; Phan, Jack; Sturgis, Erich M; Hanna, Ehab Y; Frank, Steven J; Morrison, William H; Goepfert, Ryan P; Lai, Stephen Y; Rosenthal, David I; Mendoza, Tito R; Cleeland, Charles S; Hutcheson, Kate A; Fuller, Clifton D; Garden, Adam S; Gunn, G Brandon.
Afiliação
  • Eraj SA; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Jomaa MK; School of Medicine, The University of Texas Health Science Center at Houston, McGovern School of Medicine, Houston, TX, USA.
  • Rock CD; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Mohamed ASR; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Smith BD; School of Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA.
  • Smith JB; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Browne T; Department of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Alexandria, Egypt.
  • Cooksey LC; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Williams B; School of Medicine, The University of Texas Health Science Center at Houston, McGovern School of Medicine, Houston, TX, USA.
  • Temple B; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Preston KE; School of Medicine, The University of Texas Health Science Center at Houston, McGovern School of Medicine, Houston, TX, USA.
  • Aymard JM; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Gross ND; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Weber RS; Abilene Christian University, Abilene, TX, USA.
  • Hessel AC; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Ferrarotto R; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Phan J; Abilene Christian University, Abilene, TX, USA.
  • Sturgis EM; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Hanna EY; Abilene Christian University, Abilene, TX, USA.
  • Frank SJ; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Morrison WH; Abilene Christian University, Abilene, TX, USA.
  • Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lai SY; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rosenthal DI; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mendoza TR; Department of Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cleeland CS; Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA.
  • Hutcheson KA; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fuller CD; Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Garden AS; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gunn GB; Department of Neurosurgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Radiat Oncol ; 12(1): 150, 2017 Sep 09.
Article em En | MEDLINE | ID: mdl-28888224
ABSTRACT

BACKGROUND:

Given the potential for older patients to experience exaggerated toxicity and symptoms, this study was performed to characterize patient reported outcomes in older patients following definitive radiation therapy (RT) for oropharyngeal cancer (OPC).

METHODS:

Cancer-free head and neck cancer survivors (>6 months since treatment completion) were eligible for participation in a questionnaire-based study. Participants completed the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN). Those patients ≥65 years old at treatment for OPC with definitive RT were included. Individual and overall symptom severity and clinical variables were analyzed.

RESULTS:

Of the 79 participants analyzed, 82% were male, 95% white, 41% T3/4 disease, 39% RT alone, 27% induction chemotherapy, 52% concurrent, and 18% both, and 96% IMRT. Median age at RT was 71 yrs. (range 65-85); median time from RT to MDASI-HN was 46 mos. (2/3 > 24 mos.). The top 5 MDASI-HN items rated most severe in terms of mean (±SD) ratings (0-10 scale) were dry mouth (3.48 ± 2.95), taste (2.81 ± 3.29), swallowing (2.59 ± 2.96), mucus in mouth/throat (2.04 ± 2.68), and choking (1.30 ± 2.38) reported at moderate-severe levels (≥5) by 35, 29, 29, 18, and 13%, respectively. Thirty-nine % reported none (0) or no more than mild (1-4) symptoms across all 22 MDASI-HN symptoms items, and 38% had at least one item rated as severe (≥7). Hierarchical cluster analysis resulted in 3 patient groups 1) ~65% with ranging from none to moderate symptom burden, 2) ~35% with moderate-severe ratings for a subset of classically RT-related symptoms (e.g. dry mouth, mucus, swallowing) and 3) 2 pts. with severe ratings of most items.

CONCLUSIONS:

The overall long-term symptom burden seen in this older OPC cohort treated with modern standard therapy was largely favorable, yet a higher symptom group (~35%) with a distinct pattern of mostly local and classically RT-related symptoms was identified.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioterapia / Neoplasias Orofaríngeas Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Radioterapia / Neoplasias Orofaríngeas Idioma: En Ano de publicação: 2017 Tipo de documento: Article